Search clinical trials for: ABT-652

Total 4789 results

Hutchison Medipharma Limited

Recruiting

Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT

Advanced Malignant Solid Tumors | TGCT

China
AbbVie

Completed

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

Healthy Volunteers

United States
Calithera Biosciences, Inc

Terminated

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Canada, France, United Kingdom
Calithera Biosciences, Inc

Completed

A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies

Advanced Solid Tumor and Lymphoma Malignancies

United States, Spain, Italy, United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions

Behcet Syndrome | Behcet's Disease | Neuro-Behcet's Disease

Japan
Tanox

Unknown

Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

United States
Takeda

Completed

Study of TAK-672 in Participants With Acquired Hemophilia A

Acquired Hemophilia A

Japan
VA Office of Research and Development

Recruiting

Treatments for Insomnia in Veterans With PTSD

PTSD | Insomnia

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (TURQUOISE-II)

Compensated Cirrhosis | Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (PEARL-III)

Chronic Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults (MALACHITE II)

Chronic Hepatitis C Infection
Syntrix Biosystems, Inc.
National Cancer Institute (NCI)

Not yet recruiting

Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (SYNERGY-201)

Metastatic Castration-resistant Prostate Cancer

United States
Syndax Pharmaceuticals
DevPro Biopharma

Recruiting

Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

Australia
Takeda

Active, not recruiting

A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

Japan
AbbVie

Completed

Bioavailability of ABT-450 and ABT-267 With Ritonavir

Absolute Bioavailability

United Kingdom
Quintiles, Inc.

Unknown

Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy

Head and Neck Cancer

United States
AbbVie

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection

Chronic Hepatitis C | Hepatitis C Virus
Kathleen Ludwig

Available

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients With Relapsed or Refractory ALL or LL

Relapsed Childhood ALL | Relapsed Childhood Lymphoblastic Lymphoma

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2)

Hepatitis C Virus | Chronic Hepatitis C Virus
Abbott

Completed

Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

United States, Netherlands
Abbott

Completed

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Lymphoma, Non-Hodgkin | Hodgkin's Lymphoma

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Switzerland, Canada, Denmark, Poland
Anbogen Therapeutics, Inc.

Recruiting

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Non Small Cell Lung Cancer | Advanced Solid Tumor | HER2 Mutations

Taiwan
AbbVie (prior sponsor, Abbott)

Completed

A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia

Schizophrenia

United States
AbbVie

Completed

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery

Acute Kidney Injury

United States, Denmark
AbbVie (prior sponsor, Abbott)

Completed

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

United States
AbbVie

Completed

An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors

Advanced Solid Tumors
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee

Osteoarthritis

United States
AbbVie

Terminated

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery

Cardiothoracic Surgery | Vascular Surgery

United States, Denmark
AbbVie (prior sponsor, Abbott)

Completed

Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Terminated

A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States
Abbott

Completed

To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.

Advanced Solid Tumors

United States
Abbott

Completed

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults

Healthy

United States
AbbVie

No longer available

Expanded Access to Navitoclax

Myelofibrosis | Lymphoblastic Lymphoma | Acute Lymphocytic Leukemia (ALL)

United States
AbbVie

Completed

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (ENDURANCE-5 6)

Hepatitis C Virus (HCV)

United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
C.B. Fleet Company, Inc.

Completed

Study of Efficacy of Bowel Preparation Before Colonoscopy

Bowel Cleansing Prior to Colonoscopy

United States
AbbVie

Recruiting

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Hidradenitis Suppurativa

United States, Australia, Canada, Germany, Greece, Japan, Spain, Puerto Rico
University of Florida
National Heart, Lung, and Blood Institute (NHLBI); StayWell; WellCare Health...

Completed

Wellness Achieved Through Changing Habits (The WATCH Study)

Obesity | Overweight | Weight Loss

United States
AbbVie

Completed

Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder

Major Depressive Disorder
Taisho Pharmaceutical Co., Ltd.

Completed

An Extension Study of TS-152 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Cortria Corporation
Montreal Heart Institute

Completed

A Pilot Study to Evaluate the Lipid Effects of TRIA-662

Hypertriglyceridemia | Mixed Hyperlipidemia

Canada
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
Boryung Pharmaceutical Co., Ltd

Completed

Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K) (Fimasartan)

Essential Hypertension
EVIVE Biotechnology
Memorial Sloan Kettering Cancer Center

Completed

Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD

Acute Graft vs Host Disease

United States
Vertex Pharmaceuticals Incorporated

Terminated

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China

Multiple Myeloma | Non-Hodgkin Lymphoma

China
Boryung Pharmaceutical Co., Ltd

Completed

Efficacy of fimaSartan on arTerIal stiFFness iN patiEntS With HypertenSion (STIFFNESS)

Hypertension

Korea, Republic of
University of Pennsylvania

Active, not recruiting

CART22 Alone or in Combination With huCART19 for ALL

Refractory Acute Lymphoblastic Leukemia | Chemotherapy Resistant Acute Lymphoblastic Leukemia

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I)

Hepatitis C, Chronic

3

Subscribe